Literature DB >> 19250331

Classification and design of teledermatology practice: what dermatoses? Which technology to apply?

G R Kanthraj1.   

Abstract

Dermatologists are mostly confined to urban regions and rural population is deprived of specialist care. Teledermatology Practice (TDP) is a solution to overcome this global problem. Tools for TDP includes video conference, store and forward, hybrid, mobile, satellite communication, integration model, nurse-led teledermatology, teledermatology focusing on difficult-to-manage cases, teledermoscopy, and teledermatopathology with combined applications. This article reviews the feasibility studies focusing teledermatology tools and analyses the possible options in designing TDP. Categorizing dermatoses for TDP depends on the purpose and types of technology. The dermatoses presenting from a remote geographic regions requires any of the following approaches (i) only TDP, (b) initial TDP followed by face-to-face, (iii) initial face-to-face followed by TDP and (iv) only face-to-face examination. The technology should suit the dermatoses, meet the purpose, be cost-effective and provide better management with follow-up care. We recommend store and forward as a basic TDP model as most dermatoses are diagnosed and follow-up care is delivered. Leprosy, pigmented skin lesions, leg ulcers, HIV and endemic dermatoses require screening and triage services using mobile teledermatology. Counselling and education require videoconference. Rural dermatology's camps require satellite communication mounted on a vehicle. Objective assessment (vitiligo and leg ulcer) after treatment requires integration model at a tertiary centre. Difficult-to-manage cases require second opinion using hybrid/store and forward TDP. Lower rural centre are provided with mobile/ store and forward teledermatology services. Selected or major community centre should be equipped with hybrid teledermatology and linked to a tertiary centre. This process helps healthcare administration to plan a TDP to cover all dermatoses, utilizing the available health care professional (HCP) and technology with minimum budget investment.

Entities:  

Mesh:

Year:  2009        PMID: 19250331     DOI: 10.1111/j.1468-3083.2009.03136.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  7 in total

1.  Automatic colorimetric calibration of human wounds.

Authors:  Sven Van Poucke; Yves Vander Haeghen; Kris Vissers; Theo Meert; Philippe Jorens
Journal:  BMC Med Imaging       Date:  2010-03-18       Impact factor: 1.930

2.  Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-11-01

3.  Development of a teledermatopathology consultation system using virtual slides.

Authors:  Ikunori Nakayama; Tsubasa Matsumura; Akihisa Kamataki; Miwa Uzuki; Kenji Saito; James Hobbs; Toshihide Akasaka; Takashi Sawai
Journal:  Diagn Pathol       Date:  2012-12-13       Impact factor: 2.644

4.  The suitability of gray-scale electronic readers for dermatology journals.

Authors:  Jae Eun Choi; Dai Hyun Kim; Soo Hong Seo; Young Chul Kye; Hyo Hyun Ahn
Journal:  Ann Dermatol       Date:  2014-11-26       Impact factor: 1.444

5.  On Using a Mobile Application to Support Teledermatology: A Case Study in an Underprivileged Area in Colombia.

Authors:  Juan Pablo Sáenz; Mónica Paola Novoa; Darío Correal; Bell Raj Eapen
Journal:  Int J Telemed Appl       Date:  2018-03-26

Review 6.  Applications of Space Technologies to Global Health: Scoping Review.

Authors:  Damien Dietrich; Ralitza Dekova; Stephan Davy; Guillaume Fahrni; Antoine Geissbühler
Journal:  J Med Internet Res       Date:  2018-06-27       Impact factor: 5.428

7.  Dermatologists' perceptions on the utility and limitations of teledermatology after examining 55,000 lesions.

Authors:  Mara Giavina Bianchi; Andre Santos; Eduardo Cordioli
Journal:  J Telemed Telecare       Date:  2019-08-14       Impact factor: 6.184

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.